Akèy › Skizofreni › Ohio
Etid klinik pou Skizofreni nan Ohio
18 etid pou Skizofreni ap chèche patisipan nan sit nan Ohio.
Vil nan Ohio
Tèks ofisyèl etid la (Anglè)
Evaluation of Treatment Satisfaction and KarXT Utilization Registry (RESKU)
- Westlake Brain Health, Westlake
Ap rekriteEtid obsèvasyon
Laj 18 ak plis · Tout sèks · Mizajou Sep 30, 2026 · NCT07101094Relapse Prevention Trial Evaluating KarXT Treatment in Schizophrenia
- Local Institution - 0183, Cincinnati
Ap rekriteFaz 3
Laj 18 a 65 · Tout sèks · Mizajou Sep 28, 2026 · NCT07686263NBI-1117568-SCZ3032: Long-Term Evaluation of NBI-1117568 in Adults With Schizophrenia
- Neurocrine Clinical Sites, North Canton
Ap rekriteFaz 3
Laj 18 a 65 · Tout sèks · Mizajou Sep 25, 2026 · NCT07114874Safety and Tolerability Trial of Lumateperone in Pediatric Patients With Schizophrenia, Bipolar Disorder or Autism Spectrum Disorder
- University of Cincinnati Medical Center, Cincinnati
- Charak Center for Health and Wellness, Garfield Heights
Ap rekriteFaz 3
Laj 5 a 17 · Tout sèks · Mizajou Sep 25, 2026 · NCT06229210NBI-1117568-SCZ3030: Evaluation of NBI-1117568 in Inpatient Adults With Schizophrenia
- Neurocrine Clinical Site, North Canton
Ap rekriteFaz 3
Laj 18 a 65 · Tout sèks · Mizajou Sep 25, 2026 · NCT07105098A Study of Brenipatide in Adult Participants With Schizophrenia
- Insight Clinical Trials, Independence
Ap rekriteFaz 2
Laj 18 a 55 · Tout sèks · Mizajou Sep 22, 2026 · NCT07410507A Study to Evaluate the Long-term Safety and Tolerability of Xanomeline and Trospium Chloride for the Treatment of Psychiatric Disorders in Children and Adolescents
- University of Cincinnati Cancer Institute, Cincinnati
- Local Institution - 0148, Cincinnati
Ap rekriteFaz 3
Laj 5 a 17 · Tout sèks · Mizajou Sep 22, 2026 · NCT07424404A Study to Evaluate the Effectiveness of Valbenazine in Adult Participants With Tardive Dyskinesia (TD) Who Remain Symptomatic While Receiving or After Stopping a Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor
- Neurocrine Clinical Site, Independence
Ap rekriteFaz 4
Laj 18 ak plis · Tout sèks · Mizajou Sep 18, 2026 · NCT0710511152-week Open Label Safety-Tolerability Study
- Neuro-Behavioral Clinical Research, Canton
Ap rekriteFaz 3
Laj 18 a 65 · Tout sèks · Mizajou Sep 9, 2026 · NCT07369154A Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Schizophrenia in Adolescents (EMERGENT TEEN)
- University of Cincinnati Dept of Psychiatry and Behavioral Neuroscience, Cincinnati
Ap rekriteFaz 3
Laj 13 a 17 · Tout sèks · Mizajou Sep 4, 2026 · NCT07288567A Long-Term Open-Label Study of ML-007C-MA in Adults With Schizophrenia
- Clinical Site, North Canton
- Clinical Site, West Chester
Ap rekriteFaz 2
Laj 18 a 65 · Tout sèks · Mizajou Sep 1, 2026 · NCT07459647Effectiveness and Adverse-effect Switch Evaluation of Xanomeline and Trospium Chloride (KarXT)
- Local Institution - 0031, Mason
Ap rekriteEtid obsèvasyon
Laj 18 ak plis · Tout sèks · Mizajou Aug 19, 2026 · NCT07379827REACH Study (Recovery Environments: Assessing Cognitive & Brain Health in Community Mental Health)
- Case Western Reserve University, Cleveland
Ap rekrite
Laj 18 a 50 · Tout sèks · Mizajou Aug 17, 2026 · NCT07006935Study to Evaluate Weight Gain as Assessed by Change in BMI Z-score in Pediatric Subjects With Schizophrenia or Bipolar I Disorder
- Alkermes Investigator Site, Cincinnati
- Alkermes Investigator Site, West Chester
Ap rekriteFaz 3
Laj 10 a 17 · Tout sèks · Mizajou Aug 14, 2026 · NCT05303064Study to Evaluate LB-102 for the Treatment of Adult Patients With Acute Schizophrenia
- Neuro-Behavioral Clinical Research, North Canton
Ap rekriteFaz 3
Laj 18 a 65 · Tout sèks · Mizajou Jul 27, 2026 · NCT07363577A Study to Evaluate KYN-5356 in Adults With Cognitive Impairment Associated With Schizophrenia
- Neuro-Behavioral Clinical Research, North Canton
Ap rekriteFaz 2
Laj 18 a 55 · Tout sèks · Mizajou Jun 23, 2026 · NCT07191483Normobaric Oxygen Therapy for Individuals With First-Episode Psychosis
- Harding Hospital, Columbus
Ap rekrite
Laj 15 a 35 · Tout sèks · Mizajou Feb 25, 2026 · NCT04368039Safety and Tolerability of Open-Labeled Iloperidone in Adolescents
- Vanda Investigational Site, Cincinnati
- Vanda Investigational Site, Garfield Heights
- Vanda Investigational Site, Westlake
Ap rekriteFaz 4
Laj 12 a 17 · Tout sèks · Mizajou Mar 4, 2025 · NCT05648591Sous ClinicalTrials.gov, done yo ranmase Oct 1, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.